Late-Breaking Clinical Trials

Hear it first, here at VIVA!

Physicians and researchers from the U.S. and around the world will present the most groundbreaking research available in interventional medicine.  These highly anticipated presentations, comprised of late-breaking clinical trials, follow-up data from major randomized trials, registries and first-in-man experiences with novel devices or drugs will be presented for the first time at VIVA 17.  A multidisciplinary, international, panel of experts in the field including, physicians, scientists and regulators, will ask questions and shed light on the lasting impact of the research results presented.

Abstract Submissions

The abstract submission process is now open. Please read the abstract submission guidelines carefully before submitting your abstract for consideration. A limited number of abstracts will be accepted for presentation. Accepted Late Breaking Clinical Trials will be presented during the general session at two separate sessions each day on Tuesday and Wednesday, September 12 and 13.  Presentations will be brief, and presenters will also answer questions posed by a panel of experts as well as the audience. This year, VIVA will work with media by providing an on-line Press room, a press room on-site, press conferences and press releases featuring the late-breaking clinical trials prior to and during VIVA 17.

Submission Guidelines


Research must be original and may not have been presented prior to presentation at VIVA.

Abstract submissions should address areas of endovascular medicine and report the results of:  
  • Clinical studies
  • Basic science investigations
  • Pre-clinical studies
Abstract submissions must include:  
  • Trial name
  • Purpose
  • Materials and Methods
  • Results
  • Conclusions
  • Total abstract length may not exceed 2,500 characters, exclusive of Title or figures.
The following information must be provided upon submission:  
  • Submitter Name
    • Primary Contact name
    • Organization/institution
    • Phone number
    • E-mail address
  • Names of up to three authors
  • Name of who will present the abstract if selected
    • E-mail
    • Phone number
  • Research supported/funded by: Company or entity name
  • Six-word title for abstract presentation
  Abstracts will be selected based on the following criteria:
    • Interest to field
    • Research methods
    • Quality of data
    • Primary endpoint presented
Notification of acceptance or rejection of abstracts will be sent on or around July 22, 2017.


Submitted abstracts will be reviewed after the submission deadline. Notification of acceptance will be sent on or around July 22, 2017. The acceptance letter will include complete information regarding presentation of abstracts including date and time.    If you have questions please contact Rachel DeLuna via e-mail: